Skip to search formSkip to main contentSkip to account menu

SB 1518

Known as: SB-1518, SB1518 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pacritinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1… 
Review
2013
Review
2013
Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
Introduction: The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway mediates signaling by… 
Highly Cited
2012
Highly Cited
2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
PURPOSE The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the… 
Highly Cited
2012
Highly Cited
2012
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly… 
2012
2012
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent…
Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within… 
Highly Cited
2011
Highly Cited
2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus…
Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2(V617F)), a tyrosine kinase critically involved in receptor… 
Highly Cited
2011
Highly Cited
2011
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its… 
Highly Cited
2011
Highly Cited
2011
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
Abstract 282 Background: The JAK2V617F mutation has been linked to the pathogenesis of myeloproliferative neoplasia. Pacritinib… 
2011
2011
Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
6515 Background: The JAK2V617F mutant enzyme has been linked to the pathogenesis of myeloproliferative neoplasms. SB1518 is a… 
Highly Cited
2009
Highly Cited
2009
Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.
Abstract 3905 Poster Board III-841 Mutation of Janus Associated Kinase 2 (JAK2) at amino acid 617 and the resulting… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)